A complex $26 billion global deal reaches a critical juncture on Friday: Drug companies must decide whether to walk away from an agreement to provide funds to nearly all 50 states and U.S. territories to abate costs caused by the opioid crisis. A key factor in that decision is how many of the thousands of cities and counties within each state chose to participate.